Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with a 10.6% revenue increase and a 14.9% rise in adjusted EBITDA. Share repurchases and dividends further bolster shareholder confidence. The Q&A revealed management's proactive approach to potential risks like benefit expenses and supply costs, without significant concerns. Despite some uncertainties in future costs and trends, the optimistic guidance and strategic expansion plans, such as increased partnerships, suggest a positive outlook for stock price movement.
Revenue $1.46 billion, increased 10.6% year-over-year, driven by a 6.3% increase in total discharges and a 3.9% increase in net revenue per discharge.
Adjusted EBITDA $313.6 million, increased 14.9% year-over-year, attributed to revenue growth and improved operational efficiency.
Total Discharges Increased 6.3% year-over-year, with same-store discharges growing 4.4%.
Net Revenue per Discharge Increased 3.9% year-over-year, higher than anticipated due in part to favorable payer mix.
Adjusted Free Cash Flow $222.4 million, increased 32.7% year-over-year, primarily used for capacity expansions.
Benefits Expense per FTE Increased 14% year-over-year, driven by an increase in the severity and frequency of group medical claims.
Net Leverage 2.1 times at quarter end, improved from 2.2 times at year-end.
Unrestricted Cash $95.8 million at quarter end, with no amounts drawn on the $1 billion revolving credit facility.
Share Repurchase 333,679 shares repurchased for a total of $32.1 million.
Cash Dividend Declared a cash dividend of $0.17 per share.
New Hospital Openings: Opened a new 40-bed joint venture hospital in Athens, Georgia, and plans to open 6 de novos with a total of 300 beds, including a 50-bed freestanding satellite hospital.
Bed Expansion Plans: Increased bed expansion plans to add approximately 120 beds to existing hospitals in both 2026 and 2027.
Revenue Growth: First quarter revenues increased 10.6% to $1.46 billion.
Adjusted EBITDA Growth: Adjusted EBITDA increased 14.9% to $313.6 million.
Discharge Growth: Total discharge growth of 6.3% and same-store discharges grew 4.4%.
Turnover Rates: Annualized RN turnover decreased to 20.1% from 20.4% and therapist turnover decreased to 6.3% from 7.7%.
Free Cash Flow: Adjusted free cash flow increased 32.7% to $222.4 million.
Leadership Changes: Pat Tuer promoted to Chief Operating Officer to oversee hospital operations across the organization.
Increased Guidance: Raised 2025 guidance for net operating revenue to $5.85 billion - $5.925 billion and adjusted EBITDA to $1.185 billion - $1.220 billion.
Regulatory Risks: The company faces uncertainties related to regulatory developments that could impact its operations and financial performance.
Volume and Bad Debt Trends: There are risks associated with volume fluctuations and bad debt trends that may cause actual results to differ from projections.
Cost Trends: Rising costs, particularly in benefits expenses per FTE, are expected to remain elevated, impacting overall profitability.
Labor Costs: Premium labor costs, although declining, still represent a significant expense, and any future increases could affect financial performance.
Economic Factors: The company is subject to economic factors that could influence demand for inpatient rehabilitation services and overall financial health.
Supply Chain Challenges: The company is expanding its capacity, which may expose it to supply chain challenges related to construction and staffing for new facilities.
New Hospital Openings: In Q1, we opened a new 40-bed joint venture hospital in Athens, Georgia, and plan to open 6 de novos with a total of 300 beds as well as a 50-bed freestanding satellite hospital.
Bed Expansion Plans: We anticipate adding another 125 to 145 beds to existing hospitals in 2025, and approximately 120 beds in both 2026 and 2027.
Leadership Changes: Pat Tuer has been promoted to Chief Operating Officer to oversee hospital operations, reflecting significant growth and a robust development pipeline.
Revenue Guidance: Raising 2025 net operating revenue guidance to $5.85 billion to $5.925 billion.
Adjusted EBITDA Guidance: Raising 2025 adjusted EBITDA guidance to $1.185 billion to $1.220 billion.
Adjusted EPS Guidance: Raising 2025 adjusted earnings per share guidance to $4.85 to $5.10.
Free Cash Flow Guidance: Expecting full year adjusted free cash flow of $620 million to $715 million.
Cash Dividend: Declared a cash dividend of $0.17 per share.
Share Repurchase: Repurchased 333,679 shares of common stock for a total of $32.1 million.
The earnings call summary and Q&A indicate positive sentiment: strong financial metrics, optimistic guidance, and strategic expansion plans. Despite a decrease in adjusted free cash flow, year-to-date growth is robust. The focus on bed expansion and reduced premium labor costs are favorable. However, management's lack of clarity on certain issues and the absence of a market cap metric slightly temper the outlook. Overall, the strategic initiatives and positive guidance suggest a stock price increase of 2% to 8% over the next two weeks.
The earnings call summary and Q&A session indicate positive financial metrics, such as raised guidance for revenue, EBITDA, and EPS for 2025, and strong free cash flow expectations. The company is expanding capacity with new projects and partnerships, and AI is enhancing operations. While there are concerns about management's clarity on certain issues, the overall sentiment is positive, especially with raised guidance and expansion plans. The market strategy and shareholder return plans are also favorable, suggesting a positive stock price movement.
The earnings call indicates strong financial performance with a 10.6% revenue increase and a 14.9% rise in adjusted EBITDA. Share repurchases and dividends further bolster shareholder confidence. The Q&A revealed management's proactive approach to potential risks like benefit expenses and supply costs, without significant concerns. Despite some uncertainties in future costs and trends, the optimistic guidance and strategic expansion plans, such as increased partnerships, suggest a positive outlook for stock price movement.
The earnings call presents strong financial performance with revenue and EBITDA growth, positive cash flow, and strategic positioning in a growing market. The Q&A section reveals management's confidence in labor efficiency and growth strategy, despite some uncertainties in regulatory and economic factors. The share repurchase and cash dividend enhance shareholder returns. The lack of specific guidance on some questions is a minor concern, but overall, the positive financial metrics and optimistic market positioning suggest a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
